PLYMOUTH, Minn., May 22, 2017 -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, as well as the treatment of patients with Eustachian tube dysfunction, today announced that the CMS has established a unique billing code and payment for endoscopic balloon dilation to treat Eustachian tube dysfunction (ETD). The code, C9745, will become effective July 1, 2017 and will facilitate payment for the outpatient treatment of ETD using balloon dilation in hospitals and ambulatory surgery centers (ASC).
“We are pleased by CMS’s decision to establish payment for endoscopic balloon dilation to treat ETD,” said Robert White, President and Chief Executive Officer of Entellus Medical. “The new payment code is associated with a national average payment of $4,130 in the hospital outpatient department, a payment that is consistent with those made for balloon dilations of the various sinus cavities in patients with chronic and recurring acute sinusitis. With the creation of a unique code and payment that is intended to cover the cost of the device and procedure, CMS removed one of the biggest obstacles to providers who seek to bring this innovative new treatment to their patients.”
C codes are unique temporary pricing codes that were initially established by CMS for the Hospital Outpatient Prospective Payment System (HOPPS) to promote the adoption of new medical technology that otherwise had no codes to facilitate payment. These payment codes are typically available for two to three years and Entellus believes, based on long-standing CMS policy, that billing code and payment for endoscopic balloon dilation to treat ETD will be effective through the end of 2019. C codes are used on Medicare HOPPS claims but may also be recognized on claims from other providers or by other payment systems.
About Entellus Medical, Inc.
Entellus Medical is a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of patients. Entellus products are used for the treatment of adult and pediatric patients with chronic and recurrent sinusitis, as well as adult patients with persistent Eustachian tube dysfunction. The Entellus Medical platform of products provides effective and easy-to-use solutions intended to help simplify everything from diagnosis and patient selection, to complex case revisions and post-operative care. Entellus Medical’s core product lines, XprESS™ ENT Dilation System, MiniFESS™ Surgical Instruments, XeroGel Nasal Dressing and FocESS™ Imaging & Navigation, combine to enable ENT physicians to conveniently and comfortably perform a broad range of procedures in the office and simplify treatment based in the operating room. Entellus Medical is committed to broadening its product portfolio with high-quality and purposeful innovations for the global ENT market.
Contact: Lynn Pieper Lewis 415-937-5402 [email protected]


DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes
European Car Sales Surge in March as EV and Hybrid Demand Accelerates
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs
John Ternus Signals Apple’s Future with Product-First AI Strategy
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 



